Back to top

Analyst Blog

BioLineRx (BLRX) announced new data from a phase IIa study on its pipeline candidate BL-7040. BioLineRx is developing BL-7040 for the treatment of inflammatory bowel disease (IBD). Results revealed significant improvement in disease measurements in biopsies taken from IBD patients treated with BL-7040. The histological and biochemical analyses of inflammation indicators back the initial positive results of the study, reported in April 2013. The initial results revealed that BL-7040 was safe and effective in treating patients suffering from ulcerative colitis which is a form of IBD.

In the phase IIa study, Biopsies taken from participants before and after treatment were collected and randomly assigned to either a histological evaluation or to an assessment for levels of cytokines, considered as pro-inflammatory bio-markers. Histological evaluation in patients treated with BL-7040 revealed significant reduction in neutrophil levels.

The level of the pro-inflammatory cytokine - interleukin 6 (IL-6) is an additional measure of IBD severity. Significant reduction was also seen in IL-6 in patients treated with BL-7040. Data also showed clinical improvement in patients with reduced cytokine levels.

We note that in Jun 2011, BioLineRx entered into a licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. for BL-7040.

BioLineRx mentioned in its press release that sales generated from existing IBD drugs in the U.S. were $5.6 billion in 2012. Companies like Johnson & Johnson (JNJ - Analyst Report) and Shire (SHPG - Analyst Report) also have a presence in the IBD market.

BioLineRx, a biopharmaceutical company, carries a Zacks Rank #4 (Sell). Investors interested in the biopharmaceutical industry may consider Actelion Ltd. (ALIOF) which carries a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%